In light of recent press, Fluxome A/S, Danish based parent to Fluxome, Inc., has issued a statement indicating it has recently filed for formal reconstruction. “This action was taken in part to preserve assets for its U.S. commercial operations for the production and selling of resveratrol,” the company said. “At this time, the Danish facility has closed its research activities during this reconstruction phase. Fluxome A/S, while in reconstruction, is in the process of obtaining additional funding to continue its operations both here and abroad and/or a sale of its assets. In the meantime, it is business as usual for the resveratrol operation and customers should not notice any disruption in supply.”